DaVita Inc - Company Profile
Powered by 
All the sales intelligence you need on DaVita Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how DaVita Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with DaVita Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
DaVita Inc (DaVita) is a healthcare provider that offers dialysis and integrated health care management services. The company offers services such as hemodialysis, peritoneal dialysis, kidney transplantation, hemodiafiltration, outpatient hemodialysis services, home-based dialysis services, hospital inpatient hemodialysis services, ESKD laboratory services, and management services. Its services cater to patients with chronic kidney disease and end-stage renal disease. The company, through its affiliates, also offers clinical research programs; a transplant software business; and innovation in digital health, pharmaceuticals, medical devices, and care delivery models. The company offers its services in the Americas, Europe, Asia, and the Middle East. DaVita is headquartered in Denver, Colorado, the US.
Headquarters
United States of America
Address
2000 16th Street, Denver, Colorado, 80202
Website
www.davita.com
Telephone
1 720 6312100
No of Employees
78,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DVA (NYSE)
Revenue (2024)
$13.6B
6.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-20.2%
(2024 vs 2023)
Market Cap*
$11.4B
Net Profit Margin (2024)
XYZ
-25.2%
(2024 vs 2023)
* As of and is in US$
DaVita Inc premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| - | - |
| Outpatient Dialysis Services | Davita |
| Hospital Inpatient Dialysis Services | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In August, the company expanded access to HD through FDA-approved Nipro ELISIO-HX dialyzers and advanced HDF pilots for the removal of middle-molecule toxins. |
| 2026 | Contracts/Agreements | In February, the company entered into an agreement with Elara Caring to provide a strategic investment. |
| 2024 | Financing Agreements | In October, DaVita Giving Foundation invested in the National Kidney Foundation's PEERS program. |
Competitor Comparison
| Key Parameters | DaVita Inc | Abbott Laboratories | Fresenius Medical Care AG & Co KGaA | Baxter International Inc | Dialysis Corp of America |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | United States of America | United States of America |
| City | Denver | Abbott Park | Bad Homburg | Deerfield | Linthicum |
| State/Province | Colorado | Illinois | Hessen | Illinois | Maryland |
| No. of Employees | 78,000 | 115,000 | 108,165 | 37,500 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pamela M. Arway | Chairman | Executive Board | 2020 | 72 |
| Javier J. Rodriguez | Director; Chief Executive Officer | Executive Board | 2019 | 55 |
| Joel Ackerman | Treasurer; Chief Financial Officer | Senior Management | 2019 | 60 |
| Christopher M. Berry | Chief Accounting Officer | Senior Management | 2023 | 51 |
| Stephanie Hendrickson | Chief People Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer